Vasopressin directly regulates cyst growth in polycystic kidney disease

Xiaofang Wang, Yanhong Wu, Christopher J. Ward, Peter C Harris, Vicente Torres

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (Pkhd1 -/-) and Brattleboro (AVP-/-) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK AVP-/- rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK AVP+/+ and PCK AVP+/- rats. The V2 receptor agonist 1-deamino-8-D-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK AVP-/- rats and aggravated the cystic disease of PCK AVP+/+ rats but did not induce cystic changes in wild-type rats. These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.

Original languageEnglish (US)
Pages (from-to)102-108
Number of pages7
JournalJournal of the American Society of Nephrology
Volume19
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Polycystic Kidney Diseases
Arginine Vasopressin
Vasopressins
Cysts
Vasopressin Receptors
Growth
Cystic Kidney Diseases
Kidney
Fluids and Secretions
Protective Agents
Deamino Arginine Vasopressin
Inborn Genetic Diseases
Renal Insufficiency
Chlorides
Down-Regulation
Animal Models
Cell Proliferation
Clinical Trials
Phenotype

ASJC Scopus subject areas

  • Nephrology

Cite this

Vasopressin directly regulates cyst growth in polycystic kidney disease. / Wang, Xiaofang; Wu, Yanhong; Ward, Christopher J.; Harris, Peter C; Torres, Vicente.

In: Journal of the American Society of Nephrology, Vol. 19, No. 1, 01.2008, p. 102-108.

Research output: Contribution to journalArticle

@article{dbf8ee079c844c30bee64a00df374535,
title = "Vasopressin directly regulates cyst growth in polycystic kidney disease",
abstract = "The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (Pkhd1 -/-) and Brattleboro (AVP-/-) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK AVP-/- rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK AVP+/+ and PCK AVP+/- rats. The V2 receptor agonist 1-deamino-8-D-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK AVP-/- rats and aggravated the cystic disease of PCK AVP+/+ rats but did not induce cystic changes in wild-type rats. These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.",
author = "Xiaofang Wang and Yanhong Wu and Ward, {Christopher J.} and Harris, {Peter C} and Vicente Torres",
year = "2008",
month = "1",
doi = "10.1681/ASN.2007060688",
language = "English (US)",
volume = "19",
pages = "102--108",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Vasopressin directly regulates cyst growth in polycystic kidney disease

AU - Wang, Xiaofang

AU - Wu, Yanhong

AU - Ward, Christopher J.

AU - Harris, Peter C

AU - Torres, Vicente

PY - 2008/1

Y1 - 2008/1

N2 - The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (Pkhd1 -/-) and Brattleboro (AVP-/-) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK AVP-/- rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK AVP+/+ and PCK AVP+/- rats. The V2 receptor agonist 1-deamino-8-D-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK AVP-/- rats and aggravated the cystic disease of PCK AVP+/+ rats but did not induce cystic changes in wild-type rats. These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.

AB - The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (Pkhd1 -/-) and Brattleboro (AVP-/-) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK AVP-/- rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK AVP+/+ and PCK AVP+/- rats. The V2 receptor agonist 1-deamino-8-D-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK AVP-/- rats and aggravated the cystic disease of PCK AVP+/+ rats but did not induce cystic changes in wild-type rats. These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.

UR - http://www.scopus.com/inward/record.url?scp=38149005366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149005366&partnerID=8YFLogxK

U2 - 10.1681/ASN.2007060688

DO - 10.1681/ASN.2007060688

M3 - Article

VL - 19

SP - 102

EP - 108

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 1

ER -